Skip to content

Study · Animal study (in vivo) · rat · 2004

6 results

Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist.

Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P

Proceedings of the National Academy of Sciences of the United States of America28 Jun 2004Cited by 83 (Europe PMC)

PMID15226502 (opens in a new tab)PMCIDPMC454387 (opens in a new tab)DOI10.1073/pnas.0400491101 (opens in a new tab)PepBankPUB-15226502
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In female rats, PT‑141 selectively stimulated solicitational (appetitive sexual) behaviors.

    In plain wordsIn female rats, PT‑141 specifically increased behaviors that invite sex.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    IncreaseSolicitational behaviors
    Study

    ratn: not reported in source

    female rat
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here we report that PT-141, a peptide analogue of alpha-melanocyte-stimulating hormone that binds to central melanocortin receptors, selectively stimulates solicitational behaviors in the female rat.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In female rats, PT‑141 did not affect lordosis.

    In plain wordsIn female rats, PT‑141 did not change lordosis, a reflex sexual posture.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    No significant changeLordosis
    Study

    ratn: not reported in source

    female rat
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This occurs without affecting lordosis, pacing, or other sexual behaviors.
    1 context sentence
    Summary · context
    Here we report that PT-141, a peptide analogue of alpha-melanocyte-stimulating hormone that binds to central melanocortin receptors, selectively stimulates solicitational behaviors in the female rat.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In female rats, PT‑141 did not affect pacing.

    In plain wordsIn female rats, PT‑141 did not change pacing of sexual contact.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    No significant changePacing
    Study

    ratn: not reported in source

    female rat
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This occurs without affecting lordosis, pacing, or other sexual behaviors.
    1 context sentence
    Summary · context
    Here we report that PT-141, a peptide analogue of alpha-melanocyte-stimulating hormone that binds to central melanocortin receptors, selectively stimulates solicitational behaviors in the female rat.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In female rats, PT‑141 did not affect other sexual behaviors.

    In plain wordsIn female rats, PT‑141 did not change other sexual behaviors.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    No significant changeOther sexual behaviors
    Study

    ratn: not reported in source

    female rat
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This occurs without affecting lordosis, pacing, or other sexual behaviors.
    1 context sentence
    Summary · context
    Here we report that PT-141, a peptide analogue of alpha-melanocyte-stimulating hormone that binds to central melanocortin receptors, selectively stimulates solicitational behaviors in the female rat.
  5. 05AnimalAnimal study (in vivo)Safety outcome

    In female rats, PT‑141 did not cause generalized motor activation.

    In plain wordsIn female rats, PT‑141 did not cause a general rise in movement.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    No significant changeGeneralized motor activation
    Study

    ratn: not reported in source

    female rat
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    PT-141 did not cause generalized motor activation
    1 context sentence
    Summary · context
    Here we report that PT-141, a peptide analogue of alpha-melanocyte-stimulating hormone that binds to central melanocortin receptors, selectively stimulates solicitational behaviors in the female rat.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In female rats, PT‑141 did not affect the perception of sexual reward.

    In plain wordsIn female rats, PT‑141 did not change how rewarding sex was perceived.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    No significant changePerception of sexual reward
    Study

    ratn: not reported in source

    female rat
    Outcome group
    Sexual function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    nor did it affect the perception of sexual reward.
    1 context sentence
    Summary · context
    Here we report that PT-141, a peptide analogue of alpha-melanocyte-stimulating hormone that binds to central melanocortin receptors, selectively stimulates solicitational behaviors in the female rat.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT04179734

Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder

Imperial College Healthcare NHS Trustn = 407 Oct 2019 to 6 Oct 2020

Hypoactive Sexual Desire Disorder

Trial pageClinicalTrials.govUpdated 9 Aug 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.